Cilostazol: Improving walking distance in patients with intermittent claudication

Expert Review of Cardiovascular Therapy

Volumn 2, Issue 4, 2004, Pages 503-509

  Collinson, Deborah J ^a   Donnelly, Richard ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Antiplatelet agents; Cilostazol; Intermittent claudication; Peripheral arterial disease; Phosphodiesterase III inhibitor; Vasodilators

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; ERYTHROMYCIN; KETOCONAZOLE; MILRINONE; NAFTIDROFURYL OXALATE; OMEPRAZOLE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; TICLOPIDINE; WARFARIN;

ANGINA PECTORIS; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HEART INFARCTION; HEART PALPITATION; HUMAN; INTERMITTENT CLAUDICATION; JAPAN; KINESIOTHERAPY; QT PROLONGATION; REVASCULARIZATION; SUDDEN DEATH; SYMPTOM; UNITED KINGDOM; UNITED STATES; WALKING;

EXERCISE TOLERANCE; HUMANS; INTERMITTENT CLAUDICATION; PHOSPHODIESTERASE INHIBITORS; TETRAZOLES; WALKING;

EID: 4043072883     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.2.4.503     Document Type: Article

References (32)

1. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N. Engl. J. Med. 344, 1608-1621 (2001).
2. Fowkes F, Housley E, Cawood E et al. Edinburgh artery study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int. J. Epidemiol. 20, 384-392 (1991).
3. Kannel WB, McGee DI. Update on some epidemiological features on intermittent claudication. J. Am. Geriatr. Soc. 33, 13-18 (1985).
4. Regensteiner JG, Steiner JF, Hiatt WR. Exercise training improves functional status in patients with peripheral arterial disease. J. Vasc. Surg. 23(1), 104-115 (1996).
5. Collinson DJ, Donnelly R. Therapeutic angiogenesis in the lower limb: can biotechnology produce an effective collateral circulation? Eur. J. Vasc. Endovasc. Surg. 28, 9-23 (2004).
6. Lederman RJ, Mendelsohn FO, Anderson RD et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomized trial. Lancet 359, 2053-2058 (2002).
7. Donnelly R, Yeung JM. Management of intermittent claudication: the importance of secondary prevention. Eur. J. Vasc. Endovasc. Surg. 23, 100-107 (2002).
8. Donnelly R. Pletal: symptom relief in intermittent claudication. Prescriber 26-32 (2003).
9. Gotoh F, Tohgi H, Hirai S et al. Cilostazol Stroke Prevention Study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J. Stroke Cerebrovasc. Dis. 9, 147-157 (2000)
10. Schrör K. The pharmacology of cilostazol. Diabetes Obes. Metab. 4, S14-S19 (2002).
11. Liu Y, Fong M, Cone J, Wang S, Yoshitake M, Kambayashi J. Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. J. Cardiovasc. Pharmacol. 36, 351-360 (2000).
12. Chapman TM, Goa KL. Cilostazol. A review of its use in intermittent claudication. Am. J. Cardiovasc. Drugs 3(2), 117-138 (2003).
13. Takahashi S, Oida K, Fujiwara R et al. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J. Cardiovasc. Pharmacol. 20, 900-906 (1992).
14. Elam MB, Heckman J, Crouse JR et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler. Thromb. Vasc. Biol. 18, 1942-1947 (1998).
15. Nishio Y, Kashiwagi A, Takahara N, Hidaka H, Kikkawa R. Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumour necrosis factor-α in vascular endothelial cells. Horm. Metab. Res. 29, 491-495 (1997)
16. Aoki M, Morishita R, Hayashi S et al. Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in a rat diabetes model. Diabetalogia 44, 1034-1042 (2001).
17. Lee T-M, Su S-F, Tsai C-H et al. Differential effects of cilostazol and pentoxyfilline on vascular endothelial growth factor in patients with intermittent claudication. Clin. Sci. (London) 101(3), 305-311 (2001).
18. Bramer SL, Forbes WP, Mallikaarjun S. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients in with intermittent claudication resulting form peripheral arterial disease. Clin. Pharmacokinet. 37, 1-11 (1999).
19. Bramer SL, Forbes WP. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics. Clin. Pharmacokinet. 37(Suppl. 2), 113-123 (1999).
20. Suri A, Forbes WP, Bramer SL. Effects of CYP3A inhibition on the metabolism of cilostazol. Clin. Pharmacokinet. 37, 61-68 (1999).
21. Mallikaarjun S, Bramer SL, Bortey E et al. Pharmacodynamic-pharmacokinetic interaction of aspirin with cilostazol. Clin. Pharmacol. Ther. 63, 231 (1998).
22. Mallikaarjun S, Mico BA, Forbes WP. A pharmacokinetic and pharmacodynamic study of the potential interaction between cilostazol and warfarin. Pharm. Res. 14, S555 (1997).
23. White DB, Comerota AJ, Schmieder EA, Throm RC, Gaughan JP, Rao AK. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J. Vasc. Surg. 38, 710-713 (2003).
24. Strandness DE Jr, Dalman RL, Panian S et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vasc. Endovasc. Surg. 36(2), 83-91 (2002).
25. Dawson DL, Cutler BS, Hiatt WR et al. A comparison of cilostazol and pentoxyfilline for treating intermittent claudication. Am. J. Med. 109(7), 523-530 (2000).
26. Beebe HG, Dawson DL, Cutler BS et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch. Intern. Med. 159(17), 2041-2050 (1999).
27. Dawson DL, Cutler BS, Meissner MH et al. Cilostazol has beneficial effects in treatment of intermittent claudication: results of a multicentre, randomized, prospective, double-blind trial. Circulation 98(7), 678-686 (1998).
28. Money SR, Herd JA, Isaacsohn JL et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral arterial disease. J. Vasc. Surg. 27(2), 267-274 (1998).
29. Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am. J. Cardiol. 90, 1314-1319 (2002).
30. Pratt CM. Analysis of the cilostazol safety database. Am. J. Cardiol. 87(12A), D28-D33 (2001).
31. Packer M, Carver JR, Rodeheffer RJ. et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N. Engl. J. Med. 325(3), 634-640 (1991).
32. Cone J, Wang S, Tandon N et al. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J. Cardiovasc. Pharmacol. 34(4), 497-504 (1999).